PharmacoEconomics - Modern pharmacoeconomics and pharmacoepidemiology (E-Journal) / ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология
Not a member yet
430 research outputs found
Sort by
Ранняя оценка – новый подход повышения эффективности процесса разработки медицинских технологий
Get PDFEarly health technologies assessment (HTA) is a form of HTA, which takes place at early stages of the life cycle of medical technology. This method allows us to optimize the design of clinical trials to prove the economic benefits of new technologies, to assess the need for follow-up phases of clinical trials, to predict the probability of formulary inclusion, and to define socially acceptable price.Ранняя оценка является формой оценки технологий здравоохранения (ОТЗ), которая проводится на начальных стадиях жизненного цикла медицинской технологии. Применение данного подхода позволяет оптимизировать дизайн клинических исследований для доказательства экономических преимуществ новой технологии, оценить необходимость проведения последующих фаз клинических исследований, спрогнозировать вероятность включения технологии (лекарственного препарата) в ограничительные перечни, а также определить приемлемую для общества цену
Эпидемиологические особенности неалкогольной жировой болезни печени в Новосибирске (Сибирский федеральный округ): региональные данные открытого многоцентрового проспективного исследования DIREG 2
Get PDFМетод «затраты-эффективность» в оценке антибиотикотерапии острого обструктивного бронхита у детей в условиях стационара
Get PDFStudy objective: pharmacoeconomic evaluation of cephalosporins, protected penicillins and macrolides, most commonly used in the treatment of acute obstructive bronchitis.Materials and methods. data file of hospitalized patients with acute obstructive bronchitis treatedby antibiotic. The study included 2259 patient’s data files. The age of patients ranged from 0 to 18 years old. «Cost-effectiveness» analysis was used for comparing of the costs and effectiveness for courses of antibiotics, used in therapy of acute obstructive bronchitis.Results. It is shown that a pharmacoeconomic standpoint, Ceftriaxone (Sintez) was the most effective antibiotic of the cephalosporin group in the treatment of acute obstructive bronchitis in children. The original drug Augmentin (Smithkline Beecham Pharmaceuticals) and generic Amoxiclav (Lek d.d) were used from the group of protected penicillins (combination amoxicillin / clavulanic acid). The effectiveness of Augmentin (0.591) and Amoxiclav (0.530) was comparable. The Augmentin’s course of therapy characterized by a lower value CER in comparison with Amoxiklav. From the pharmacoeconomic point of view treatment course of Azithromycin (Vertex) was the most appropriate of the macrolide antibiotic in the therapy of acute obstructive bronchitis,. The highest value ICER ratio was obtained for Sumamed (Teva), and it amounted to 39 367.50 rubles. Sumamed was characterized by the highest clinical efficacy. Besides Sumamed is original azithromycin. Azitromicin generics Azitral and Hemomitsin had the lowest ICER after Azithromycin (1151.67 rubles and 1812.22 rubles, respectively)
Лекарственные препараты, отпущенные больным раком молочной железы в рамках программ лекарственного обеспечения населения
Get PDFThe purpose of our research was to analyze the actual practice of medicine in patients with breast cancer in various regions of the Russian Federation in the framework of state programs of drug provision (procurement of essential drugs (EDPP) and of regional benefits (RBP)).Materials and Methods. We collected data on dispensed medicines from 42 regions of the Russian Federation, which accounted for 57.58% of the total population and 58.20% of the total number of breast cancer patients who had been registered in the oncological institutions of the Russian Federation in 2013. We collected and studied data on the antineoplastic agents (L01) and hormonal antineoplastic drugs (L02) dispensed through programs of drug supply from federal and regional budgets in 2013 in the regions of the Russian Federation for patients with a diagnosis of «malignant neoplasm of the breast» (C50 International Classification of Diseases, 10th revision).Results. The number of drugs prescribed to patients with breast cancer in studied regions ranged from 3 to 39 INNs. Among the most commonly used antineoplastic agents were trastuzumab and capecitabine (both used in 92.86% of the regions), and among hormonal antineoplastic drugs were aromatase inhibitors and tamoxifen (95.24% and 100% of the regions of the Russian Federation). Consumption of drugs varied significantly between theregions.Conclusion. Our study revealed significant differences in the consumption of antineoplastic medications among outpatients with breast cancer in different regions of the Russian Federation whose care was funded by federal and regional budgets
Клинико-экономическая оценка альтернативных вариантов питания недоношенных новорожденных в Российской Федерации
Get PDFФармакоэкономическая эффективность вакцинопрофилактики гриппа и пневмококковой инфекции у работников ОАО «РЖД» с точки зрения работодателя
Get PDFObjectives: To determine the clinical and economical effectiveness of influenza and pneumococcal vaccination in working adults without occupational exposures on respiratory diseases from an employer’s perspective. Methods. The study involved about 2,000 employees of the Joint Stock Company «Russian Railways» (JSCo «RZD») followed for 7 months during the 2013-2014 influenza season to collect data on influenza like illness (ILI) and pneumococcal respiratory like illness. Morbidity estimates from different observation groups was calculated using the Pearson χ2 criterion (with Bonferroni correction, if needed) and using the Marascuillo procedure. The calculations are performed in Microsoft Excel (the applied statistical software was not used). The author presented the method of direct and indirect costs calculation. Pharmacoeconomic evaluation for the JSCo «RZD» was defined according to the impact of the 2013 influenza vaccination programme (292.180 employees were vaccinated). Results. Acute respiratory morbidity was significantly lower in vaccinated employees than in nonvaccinated. The vaccine effectiveness was 73.9% against influenza and 84.6% against pneumococcal respiratory infections. The morbidity differences between tobacco smokers and non-smokers is not proven. Due 292.180 employees influenza immunization the direct costs for JSCo "RZD" amounted to 114.2 million roubles (2.54 million EUR), indirect costs estimated at 1.9 billion rubles (42.2 million EUR). According to the generated modelling, the pneumococcal (PPSV23) immunization programme became cost-effective starting from the second year after vaccination and should continue to increase.
Планирование объемов и финансовых затрат на оказание медицинской помощи в стационарных условиях на федеральном и региональном уровнях
Get PDFФармакоэкономические аспекты применения руфинамида при синдроме Леннокса-Гасто
Get PDFAmong epileptic encephalopathies, the Lennox–Gastaut syndrome is considered to be one of the most severe. It is a childhood-onset disease that leads to early disability and mental retardation and is associated with significant costs of medical care and patient nursing. In the Russian Federation, the supposed number of patients with the Lennox–Gastaut syndrome is between 1400 and 9240 people. Rufinamide is one of the most powerful agents being used for the adjuvant therapy of this syndrome. In order to evaluate the efficacy of the drug in this pathology, a systematic review of publications of the results of the respective clinical studies was performed. Eleven articles were selected for generation of pooled groups and meta-analysis. Rufinamide used as an adjunctive therapy has been shown to substantially increase the chances of successful result (HR=3.1 [2.0; 4.9], p=0.000). Pharmacoeconomic modelling (a decision tree type) allowed revealing that the use of rufinamide adjunctive therapy for the Lennox–Gastaut syndrome reduces total costs of treatment and nursing of these patients with minimum effect on the budget
Фармакоэкономический анализ затрат на обеспечение льготными лекарственными препаратами больных хронической обструктивной болезнью легких на территории Красноярского края
Get PDFThe purpose of this study was to conduct the analysis of the structure and the rationality of cost in particular of providing preferential medicines patients with сhronic obstructive pulmonary disease (COPD) in Krasnoyarsk region.Materials and methods. The database of Ministry of Health of Krasnoyarsk region and Territorial fund of obligatory medical insurance of Krasnoyarsk region on the released preferential preparations to patients with the code J44 on the territory of Krasnoyarsk region for 2014 was used. For the diagnosis of rationality costs method of pharmaco-economic analysis — АВС/VEN analysis — was applied.Results. Most of the costs amounted to vital medicines (99.8%) of which the maximum share of costs associated with bronchodilators (73.9%) and a combination of DDBA and inhalation GCS (18.5%). In this research the most finances was spent on Tiotropium bromide (51%), Fenoterolum/Ipratropium bromide (18.7%) and Salmeterol/ Fluticasonum (11%). The nomenclature of International unlicensed name of the drugs which are released according to preferential prescriptions for 98.9% is bound to pathogenetic therapy of COPD and doesn't contradict to the modern recommendations on a pharmacotherapy of this pathology. Most of patients were provided with the following drugs of International unlicensed name: the combined preparation of Fenoterolum/ Ipratropium bromide (72.2%), a lond-acting cholinoblocker Tiotropium bromide (38.9%) and mucolytic preparation N- Acetylcysteinum (38.7%). To the category N is referred only 3 drugs of International unlicensed name the necessary of which is in doubt.Conclusion. The ABC/ VEN analysis showed rational use of financial means on pharmacotherapy patients with COPD in Krasnoyarsk region. The list of drugs of International unlicensed name is consistent with the current recommendations for management of such patients
Соплатежи населения в системе здравоохранения: международный опыт
Get PDFThe growth of cost of healthcare services becomes more and more serious problem throughout the world. In the context of no limitations with respect to both scope of consumption and cost of the services, due to application of innovational treatment methods, the cost of medical aid, rendered to the citizens free of charge, has almost no upper limit. In light of this, the alternative strategies of more efficient and fair funding of healthcare, being the subject of this article, are searched throughout the world.Все более серьезной проблемой во всем мире становится рост стоимости медицинского обслуживания. При отсутствии ограничений как c точки зрения объемов потребления, так и стоимости услуг, в связи с применением инновационных методов лечения, стоимость медицинской помощи, оказываемой населению бесплатно, практически не имеет верхнего предела. Поэтому во всем мире идет поиск альтернативных стратегий более эффективного и справедливого финансирования здравоохранения, о которых и пойдет речь в данной статье